Back

TransMedics Group Inc

Ticker: TMDX ISIN: US89377M1099
Add to portfolio Portfolio analysis in 2min
Stock Mid-cap High beta
Market cap
$3.91B
P/E
23.41
Forward P/E
45.66
Profit margin
31.43%
Revenue growth QoQ
32.20%
Beta
2.08
$92.22 -1.47%
Price as of 2026-08-26 · NASDAQ

Performance by timeframe

Rolling returns
1 Month +20.88%
6 Months -31.47%
1 Year -21.43%
5 Years +24.41% p.a.+197.77%
Since inception +21.36% p.a.+312.43%
Calendar year returns
YTD -24.19%
2025 +95.11%
2024 -21.01%
2023 +27.88%
2022 +222.13%
2021 -3.72%

Key stats

Market cap
3.91B
P/E
23.41
Beta
2.08
52-week range
81.92 - 156.00
50-day MA
124.69
200-day MA
123.75
Section 1

Business overview

Company profile data from fundamentals.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Sector Healthcare
Industry Medical Devices
Country United States
Exchange NASDAQ
Section 2

Financial quality

Above-average volatility

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 54.24%
ROA 7.25%
Profit margin 31.43%
Operating margin 13.23%
Revenue/share TTM 17.81
Revenue TTM 605.49M
EBITDA 134.47M
Gross profit TTM 362.81M
Beta 2.08

Valuation

Trailing P/E 23.41
Forward P/E 45.66
P/B 8.27
P/S 6.46
EV/EBITDA 26.54
EV/Revenue 6.51
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 2.46
Quarterly earnings growth 11.88%
Revenue TTM 605.49M
Reported quarters 30
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Forward annual div. yield 0.00%
Last split date 0000-00-00
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price $144.73
Analyst rating 4.2222

Ownership & short interest

Shares outstanding 34.17M
Shares float 33.03M
Institutional ownership 111.36%
Insider ownership 2.95%
Short ratio 8.97
Short % of float 41.54%

Details

Instrument metadata and source update timestamps.

Symbol TMDX
Name TransMedics Group Inc
Asset type STOCK
Exchange NASDAQ
Currency USD
ISIN US89377M1099
Country USA
Code + exchange TMDX.NASDAQ
Fundamentals updated 2026-04-11

The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.

Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.

Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.

Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.

By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.

Instrument logos provided by Elbstream.